PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30179004-0 2018 HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. Ticlopidine 37-48 major histocompatibility complex, class I, A Homo sapiens 0-5 30179004-1 2018 The HLA class I allele HLA-A*33:03 is a risk factor for ticlopidine-induced liver injury. Ticlopidine 56-67 major histocompatibility complex, class I, A Homo sapiens 23-28 30179004-2 2018 Herein, we show HLA class I-restricted ticlopidine-specific CD8+ T-cell activation in healthy donors expressing HLA-A*33:03. Ticlopidine 39-50 major histocompatibility complex, class I, A Homo sapiens 112-117 23635947-8 2013 Several HLA alleles also demonstrate drug-specific associations with DILI, such as HLA-A*33:03 for ticlopidine, HLA-B*57:01 for flucloxacillin and HLA-DQA1*02:01 for lapatinib. Ticlopidine 99-110 major histocompatibility complex, class I, A Homo sapiens 83-88 28043905-16 2017 CONCLUSIONS: In a GWAS of persons of European descent with DILI, we associated HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine. Ticlopidine 149-160 major histocompatibility complex, class I, A Homo sapiens 79-84 17339877-2 2008 There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01). Ticlopidine 44-55 major histocompatibility complex, class I, A Homo sapiens 127-132 17339877-3 2008 In particular HLA-A*3303 was present in 15 (68%) of the 22 patients with ticlopidine-induced hepatotoxicity and in 12 (14%) of the 85 ticlopidine-tolerant patients (odds ratio, 13.04; 95% confidence interval (CI), 4.40-38.59; the corrected P-value (Pc)=1.24 x 10(-5)). Ticlopidine 73-84 major histocompatibility complex, class I, A Homo sapiens 14-19 17339877-3 2008 In particular HLA-A*3303 was present in 15 (68%) of the 22 patients with ticlopidine-induced hepatotoxicity and in 12 (14%) of the 85 ticlopidine-tolerant patients (odds ratio, 13.04; 95% confidence interval (CI), 4.40-38.59; the corrected P-value (Pc)=1.24 x 10(-5)). Ticlopidine 134-145 major histocompatibility complex, class I, A Homo sapiens 14-19 17339877-4 2008 HLA-A*3303 was present in 12 (86%) of the 14 patients with ticlopidine-induced cholestatic hepatotoxicity (odds ratio, 36.50; 95% CI, 7.25-183.82, Pc=7.32 x 10(-7)). Ticlopidine 59-70 major histocompatibility complex, class I, A Homo sapiens 0-5 17339877-5 2008 Ticlopidine-induced severe cholestatic hepatotoxicity occurred more frequently in subjects with HLA-A*3303 and its haplotype in Japanese patients. Ticlopidine 0-11 major histocompatibility complex, class I, A Homo sapiens 96-101